盾叶冠心宁治疗冠心病合并高同型半胱氨酸血症患者临床观察

Clinical Observation of Dunye Guan Xin Ning on the Treatment of Coronary Heart Disease Patients with Hyperhomocysteinemia

目的探讨盾叶冠心宁片对冠心病合并高同型半胱氨酸(Hcy)血症患者Hcy及血脂的影响。方法选取冠心病合并高Hcy血症患者120例,采用随机数字表法分为观察组与对照组,各60例,观察组给予基础治疗+盾叶冠心宁片;对照组给予基础治疗+叶酸及甲钴胺片。治疗30d后观察患者血清Hcy、总胆固醇(TC)、低密度脂蛋白-C(LDL-C)、高密度脂蛋白-C(HDL-C)及三酰甘油(TG)变化。结果治疗后,2组Hcy较前均有下降,差异无统计学意义(P>0.05);观察组TC(3.72±0.53)mmol/L、LDL-C(1.67±0.29)mmol/L及TG(1.04±0.48)mmol/L,较对照组的(3.91±0.45)mmol/L、(1.82±0.27)mmol/L及(1.21±0.41)mmol/L水平下降更明显,差异有统计学意义(P<0.05);观察组HDL-C(1.04±0.25)mmol/L,较对照组的(1.04±0.22)mmol/L略有升高,差异无统计学意义(P>0.05)。结论盾叶冠心宁片可降低Hcy水平,调节血脂。

Objective To investigate the effect of the prescription of DunyeGuanxinning tablet on homocysteine and blood lipid in patients with coronary heart disease complicated with Hyperhomocysteinemia. Methods 120 patients with coronary heart disease complicated with Hyperhomocysteinemia were selected. and were randomly divided into observation group (60 cases given basic treatment+Dunye Guanxinning tablet) and control group (60 cases, given basic treatment+folic acid and methylcobalamin). After treatment for 30 days, serum homocysteine (Hcy), total cholesterol (TC), low-density lipoprotein-C(LDL-C),high-density lipoprotein-C(HDL-C)and triglyceride (TG) were observed. Results After treatment, homocysteine the two groups decreased than before. There was no significant difference between the two groups ( P >0.05). The total cholesterol in the observation group decreased (3.72±0.53)mmol/L, low density lipoprotein-C(1.67±0.29)mmol/L and triglyceride levels (1.04± 0.48)mmol/L decreased more than the control group. There was significant difference between the two groups ( P <0.05). two groups of High density lipoprotein-C observation group (1.04±0.25)mmol/L, control group (1.04±0.22)mmol/L were slightly higher. The difference was not statistically significant ( P >0.05). Conclusion DunyeGuanxinning tablet can lower Hyperhomocysteinemia levels, and has certain clinical effect on regulating blood lipid.